Beneficial weight-loss properties of glucagon-like peptide-1 receptor agonists (GLP-1RA) in obese people, with corresponding improvements in cardiometabolic risk factors, are well established. OKV-119 is an investigational drug delivery system that is being developed for the long-term delivery of the GLP-1RA exenatide to feline patients. The purpose of this study was to evaluate the drug release characteristics of subcutaneous OKV-119 implants configured to release exenatide for 84 days. Following a 7-day acclimation period, five purpose-bred cats were implanted with OKV-119 protypes and observed for a 112-day study period. Food intake, weekly plasma exenatide concentrations and body weight were measured. Exenatide plasma concentrations were detected at the first measured timepoint (Day 7) and maintained above baseline for over 84 Days. Over the first 28 days, reduced caloric intake and a reduction in body weight were observed in four of five cats. In these cats, a body weight reduction of at least 5% was maintained throughout the 112-day study period. This study demonstrates that a single OKV-119 implant can deliver the GLP-1RA exenatide for a months long duration. Results suggest that exposure to exenatide plasma concentrations ranging from 1.5 ng/ml to 4 ng/ml are sufficient for inducing weight loss in cats.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102179 | PMC |
| http://dx.doi.org/10.1186/s12917-024-04051-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
Diabetes Obes Metab
January 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Aims: To explore the relationship between weight loss and insulin sensitivity in response to tirzepatide or semaglutide.
Materials And Methods: We conducted a post hoc exploratory analysis of a 28-week, double-blind, randomized trial in people with type 2 diabetes treated with metformin, randomized to tirzepatide 15 mg, semaglutide 1 mg or placebo. We evaluated the relationship between change in body weight and change in insulin sensitivity determined from hyperinsulinemic euglycemic clamp (M value), or from mixed-meal tolerance testing (Matsuda index).
Pre-pregnancy BMI modifies the associations between triglyceride-glucose index in early pregnancy and adverse perinatal outcomes: a 5-year cohort study of 67,936 women in China.
Diabetol Metab Syndr
January 2025
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, No. 910, Hengshan Rd., Shanghai, 200030, China.
Background: Triglyceride-glucose (TyG) index was suggested as a possible surrogate for insulin resistance and a predictor for cardiovascular diseases and diabetes in the non-pregnant population. However, the relationship between TyG index in early pregnancy and adverse pregnancy outcomes (APOs), and the contribution of pre-pregnancy body mass index (BMI) was still illusive.
Methods: A large retrospective cohort study involving 67,936 pregnant Chinese women between 2017 and 2022 was conducted.
Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.
Reprod Biol Endocrinol
January 2025
Departments of Internal Medicine and Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 330 Cedar St, New Haven, CT, 06510, USA.
Background: Overweight and obesity-chronic illnesses in which an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass resulting in adverse metabolic, biomechanical, and psychosocial health consequences-negatively impact female fertility. Adverse conception outcomes are multifactorial, ranging from poor oocyte quality and implantation issues to miscarriages and fetal health issues. However, with the advent of novel pharmacologic agents, significant weight loss can be achieved, improving the chances of healthy pregnancies, and their use should be considered during periconceptual counseling.
View Article and Find Full Text PDFImpact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes.
Curr Diab Rep
January 2025
Facultad de Farmacia y Bioquímica, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC-UBA), Buenos Aires, Argentina.
Purpose Of Review: This article explores the cardiovascular effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM), with a particular focus on their impact on lipid profiles. As evidence grows of the cardiovascular benefits of SGLT2i beyond glucose control, it is essential to better understand their effects on lipoproteins and their impact on cardiovascular disease.
Recent Findings: SGLT2i have shown significant cardiovascular benefits in patients with type 2 diabetes mellitus, beyond their role in lowering blood glucose.
Associations between the conicity index and kidney stone disease prevalence and mortality in American adults.
Sci Rep
January 2025
Department of Urology, The First Hospital of Jilin University, No. 1 Xinmin Street, Chaoyang District, Changchun City, Jilin Province, China.
Kidney Stone Disease (KSD) is a prevalent urological condition, while abdominal obesity is on the rise globally. The conicity index, measuring body fat distribution, is crucial but under-researched in its relation to KSD and all-cause mortality. This study, using data from 59,842 participants in the NHANES (2007-2018), calculated the conicity index from waist circumference, height, and weight.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!